MA28514B1 - Formulations pharmaceutiques pour inhalateur de poudre seche comprenant un principe actif agissant meme a faible dosage - Google Patents

Formulations pharmaceutiques pour inhalateur de poudre seche comprenant un principe actif agissant meme a faible dosage

Info

Publication number
MA28514B1
MA28514B1 MA29363A MA29363A MA28514B1 MA 28514 B1 MA28514 B1 MA 28514B1 MA 29363 A MA29363 A MA 29363A MA 29363 A MA29363 A MA 29363A MA 28514 B1 MA28514 B1 MA 28514B1
Authority
MA
Morocco
Prior art keywords
active ingredient
dry powder
pharmaceutical formulations
powder inhaler
low dosage
Prior art date
Application number
MA29363A
Other languages
English (en)
Inventor
Roberto Bilzi
Angela Armanni
Roberto Rastelli
Daniela Cocconi
Rossella Musa
Original Assignee
Chiesi Farma Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34962706&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA28514(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiesi Farma Spa filed Critical Chiesi Farma Spa
Publication of MA28514B1 publication Critical patent/MA28514B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA29363A 2004-03-17 2006-10-02 Formulations pharmaceutiques pour inhalateur de poudre seche comprenant un principe actif agissant meme a faible dosage MA28514B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04006430 2004-03-17

Publications (1)

Publication Number Publication Date
MA28514B1 true MA28514B1 (fr) 2007-04-03

Family

ID=34962706

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29363A MA28514B1 (fr) 2004-03-17 2006-10-02 Formulations pharmaceutiques pour inhalateur de poudre seche comprenant un principe actif agissant meme a faible dosage

Country Status (19)

Country Link
US (1) US8153104B2 (fr)
EP (1) EP1729728B1 (fr)
KR (1) KR20060130216A (fr)
CN (1) CN1942172B (fr)
AR (1) AR049010A1 (fr)
AU (1) AU2005224008B2 (fr)
BR (1) BRPI0508170A (fr)
CA (1) CA2560226C (fr)
ES (1) ES2566618T3 (fr)
JO (1) JO3102B1 (fr)
MA (1) MA28514B1 (fr)
MX (1) MXPA06010593A (fr)
NO (1) NO342481B1 (fr)
NZ (1) NZ549870A (fr)
PE (1) PE20060716A1 (fr)
RU (1) RU2371171C2 (fr)
TN (1) TNSN06277A1 (fr)
WO (1) WO2005089717A1 (fr)
ZA (1) ZA200607700B (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1944018A1 (fr) 2007-01-10 2008-07-16 CHIESI FARMACEUTICI S.p.A. Particules micronisées comprenant des principes actifs agissant même à faible dose pour préparations en poudre pour inhalation
EP2124915A2 (fr) * 2007-02-19 2009-12-02 Cipla Limited Combinaisons pharmaceutiques
EP2191821A1 (fr) 2008-11-26 2010-06-02 CHIESI FARMACEUTICI S.p.A. Microparticles contenant une sel de 8-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1H)-quinolinone avec adhesion ameliorée pour l'inhalation de poudre sèche
TWI491416B (zh) * 2008-12-24 2015-07-11 Daiichi Sankyo Co Ltd 吸入用乾燥粉末醫藥組成物
CA2770714A1 (fr) * 2009-08-27 2011-03-17 Stc.Unm Procedes et systemes de dosage et d'enduction de poudres destinees a l'inhalation sur des particules supports
EP2360147A1 (fr) * 2010-02-22 2011-08-24 CHIESI FARMACEUTICI S.p.A. Procédé de préparation de particules crystallines d'un sel de 8-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino] ethyl]-2(1H)-quinolinone (carmoterol)
WO2011120779A1 (fr) * 2010-04-01 2011-10-06 Chiesi Farmaceutici S.P.A. Procédé de préparation de particules d'excipient pour poudres sèches à inhaler
DE102011102614A1 (de) * 2011-05-27 2012-11-29 Roland Nied Verfahren zum Betrieb einer Strahlmühle sowie Strahlmühle
WO2013077830A1 (fr) * 2011-11-25 2013-05-30 Mahmut Bilgic Associations actives sur le plan synergique contenant du roflumilast et du carmotérol
HUE069624T2 (hu) * 2012-01-25 2025-03-28 Chiesi Farm Spa Kortikoszteroidot és béta-adrenerg szert tartalmazó száraz porkészítmény inhalálással történõ beadásra
CN107875127A (zh) * 2012-02-28 2018-04-06 艾塞尤提卡控股公司 可吸入药物组合物
KR20140147891A (ko) 2012-04-13 2014-12-30 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 응집체 입자
JP5087182B1 (ja) * 2012-06-13 2012-11-28 クリニプロ株式会社 吸入用パウダーの製造方法
KR20180092324A (ko) * 2013-03-13 2018-08-20 포레스트 래보러토리즈 홀딩스 리미티드 미분화된 약제학적 조성물
GB201305825D0 (en) 2013-03-28 2013-05-15 Vectura Ltd New use
LT3019153T (lt) * 2013-07-11 2018-11-26 Chiesi Farmaceutici S.P.A. Sausų miltelių kompozicija, apimanti anticholinerginį agentą, kortikosteroidą ir beta-adrenerginį agentą, skirta įvedimui inhaliacijos pagalba
US9427376B2 (en) * 2013-10-10 2016-08-30 Chiesi Farmaceutici S.P.A. Process for preparing pharmaceutical formulations for inhalation comprising a high-dosage strength active ingredient
CN104800192A (zh) * 2014-01-27 2015-07-29 成都英诺新科技有限公司 一种罗氟司特吸入粉雾剂及制备方法
HRP20260435T1 (hr) 2014-09-09 2026-05-08 Vectura Limited Formulacija koja sadrži glikopirolat, postupak i uređaj
US10583085B2 (en) * 2017-05-17 2020-03-10 Chiesi Farmaceutici S.P.A. Carrier particles for dry powder formulations for inhalation
CN109200034A (zh) * 2017-06-30 2019-01-15 正大天晴药业集团股份有限公司 一种可吸入干粉形式的组合物及其制备方法
GB201911517D0 (en) * 2019-08-12 2019-09-25 Verona Pharma Plc Pharmaceutical composition
JP7649441B2 (ja) * 2019-12-16 2025-03-21 シージェン インコーポレイテッド 賦形剤の高速液体クロマトグラフィー定量法
WO2021236570A1 (fr) * 2020-05-18 2021-11-25 Anovent Pharmaceutical (U.S.), Llc Formulation pharmaceutique contenant du remdésivir et ses métabolites actifs pour inhalation de poudre sèche

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0441740B1 (fr) 1990-01-29 1993-09-22 Ciba-Geigy Ag Procédé et dispositif pour le dosage d'une poudre à grains fins
US6673335B1 (en) 1992-07-08 2004-01-06 Nektar Therapeutics Compositions and methods for the pulmonary delivery of aerosolized medicaments
IS1796B (is) * 1993-06-24 2001-12-31 Ab Astra Fjölpeptíð lyfjablanda til innöndunar sem einnig inniheldur eykjaefnasamband
SE9700135D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
US20010006939A1 (en) * 1997-10-03 2001-07-05 Ralph W. Niven Secretory leukocyte protease inhibitor dry powder pharmaceutical compositions
IT1309592B1 (it) * 1999-03-05 2002-01-24 Chiesi Farma Spa Particelle veicolo modificate da utilizzarsi nella preparazione diformulazioni farmaceutiche sotto forma di polimeri per inalazione e
GB9925934D0 (en) * 1999-11-03 1999-12-29 Glaxo Group Ltd Novel apparatus and process
PE20011227A1 (es) * 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
MXPA03001092A (es) * 2000-08-07 2003-09-25 Nektar Therapeutics Al Corp Polvos de proteina de haz de 4 helices secados por rocio, inhalables, que tienen agregacion minimizada.
US6587025B2 (en) * 2001-01-31 2003-07-01 Vishay Dale Electronics, Inc. Side-by-side coil inductor
EP1643974A1 (fr) * 2003-07-11 2006-04-12 Glaxo Group Limited Formulations pharmaceutiques inhalables contenant un ester de sucre
EP2080508A1 (fr) * 2008-01-15 2009-07-22 CHIESI FARMACEUTICI S.p.A. Formulation de poudre sèche comprenant un médicament anticholinérgique

Also Published As

Publication number Publication date
EP1729728B1 (fr) 2016-03-16
CA2560226C (fr) 2013-07-23
BRPI0508170A (pt) 2007-08-07
JO3102B1 (ar) 2017-09-20
US8153104B2 (en) 2012-04-10
EP1729728A1 (fr) 2006-12-13
CN1942172B (zh) 2010-10-06
TNSN06277A1 (en) 2007-12-03
CA2560226A1 (fr) 2005-09-29
RU2006133038A (ru) 2008-03-20
NZ549870A (en) 2010-05-28
ZA200607700B (en) 2008-05-28
KR20060130216A (ko) 2006-12-18
ES2566618T3 (es) 2016-04-14
AU2005224008B2 (en) 2010-09-16
AR049010A1 (es) 2006-06-21
NO342481B1 (no) 2018-05-28
CN1942172A (zh) 2007-04-04
PE20060716A1 (es) 2006-07-25
US20070202053A1 (en) 2007-08-30
HK1101346A1 (en) 2007-10-18
MXPA06010593A (es) 2007-02-16
NO20064161L (no) 2006-10-17
AU2005224008A1 (en) 2005-09-29
RU2371171C2 (ru) 2009-10-27
WO2005089717A1 (fr) 2005-09-29

Similar Documents

Publication Publication Date Title
TWI366460B (en) Cannabinoid active pharmaceutical ingredient for improved dosage forms
HRP20181819T1 (hr) Formulacija krutog farmaceutskog oblika doziranja koja sadrži lopinavir
EP1909772A4 (fr) Formulation pour l'administration transdermique de medicaments
WO2006124047A3 (fr) Formulations pharmaceutiques contenant des microparticules ou des nanoparticules d'un agent d'administration
HUE043897T2 (hu) Lipofil hatóanyagot tartalmazó készítmények és eljárás elõállításukra
EP1635762A4 (fr) Poudres pharmaceutiques faiblement dosees inhalables
EP2078731A4 (fr) Composition pharmaceutique comprenant un anticorps anti-hb-egf comme ingrédient actif
DK2451445T3 (da) Fremgangsmåde til at tørre bibw2992, dets salte og faste farmaceutiske formuleringer omfattende denne aktive ingrediens
IL195269A0 (en) Pharmaceutical formulations for the sustained release of active ingredient(s), as well as their applications, especially therapeutic
IL177869A0 (en) A stable pharmaceutical composition comprising an acid labile drug
ZA200804477B (en) Agrochemical nanoparticulate active ingredient formulations
BRPI0807285A2 (pt) "composição, método para preparar composição farmacêutica, forma unitária de dosagem, método para admnistrar um agente biologicamente ativo a um animal necessitando o agente, método para aumentar a biodisponibilidade de um agente biologicamente ativo, método para preparar uma composição e composto"
ZA200709788B (en) Cannabinold active pharmaceutical ingredient for Improved dosage forms
EP2093237A4 (fr) Agent anticancéreux comprenant un anticorps anti-hb-egf en tant qu'ingrédient actif
ZA200801575B (en) Pharmaceutical formulations/composition of guanfacine suitable for single dose form administration daily
IL190698A0 (en) Nanoparticulate active ingredient formulations
EP2231189A4 (fr) Système d'administration de médicament pour administrer des substances pharmaceutiquement actives pauvrement hydrosolubles
WO2007014124A3 (fr) Formes posologiques et preparations a charge medicamenteuse elevee
BRPI0507225A2 (pt) formulações estáveis de solução farmacêutica para inaladores pressurizados de dose medida
FR2904219B1 (fr) Microparticules a base de copolymere amphiphile et de principe(s) actif(s) a liberation modifiee et formulations pharmaceutiques en contenant
WO2008065144A3 (fr) Préparations galéniques de composés organiques
EA201001125A1 (ru) Фармацевтические композиции, включающие n-[2-(диэтиламино)этил]-5-[(5-фтор-1,2-дигидро-2-оксо-3н-индол-3-илиден)метил]-2,4-диметил-1н-пиррол-3-карбоксамид
WO2007011958A3 (fr) Formes posologiques intra-buccales de glucagon
ATE460934T1 (de) Pharmazeutische zubereitungen von ciprofloxacin
ATE457721T1 (de) An titandioxidnanopartikeln absorbierte pharmazeutische wirkstoffe enthaltende pharmazeutische formulierungen